Academic literature on the topic 'Acido Gadoxetico'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Acido Gadoxetico.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Acido Gadoxetico"
Koh, Dow-Mu, Ahmed Ba-Ssalamah, Giuseppe Brancatelli, Ghaneh Fananapazir, M. Isabel Fiel, Satoshi Goshima, Sheng-Hong Ju, et al. "Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging." European Radiology 31, no. 8 (February 1, 2021): 5615–28. http://dx.doi.org/10.1007/s00330-020-07637-4.
Full textTsuboyama, Takahiro, Gregor Jost, Tonsok Kim, Masatoshi Hori, Hiromitsu Onishi, Hubertus Pietsch, and Noriyuki Tomiyama. "Experimental studies on artifacts and tumor enhancement on gadoxetic acid-enhanced arterial phase liver MRI in a rabbit VX2 tumor model." Acta Radiologica 59, no. 9 (December 13, 2017): 1029–37. http://dx.doi.org/10.1177/0284185117747134.
Full textSeidensticker, Max, Ingo G. Steffen, Irene Bargellini, Thomas Berg, Alberto Benito, Bernhard Gebauer, Roberto Iezzi, et al. "Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort." Current Oncology 29, no. 2 (January 27, 2022): 565–77. http://dx.doi.org/10.3390/curroncol29020051.
Full textBai, Chongxin, Kewen Liu, Shi Chen, Zhao Li, Weida Xie, Qingjia Bao, and Chaoyang Liu. "Dual-domain unsupervised network for removing motion artifact related to Gadoxetic acid-enhanced MRI." Journal of Physics: Conference Series 2258, no. 1 (April 1, 2022): 012037. http://dx.doi.org/10.1088/1742-6596/2258/1/012037.
Full textKаrmаzаnovsky, G. G., and A. A. Volobueva. "Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoxetic Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma." Journal of radiology and nuclear medicine 102, no. 5 (November 17, 2021): 284–95. http://dx.doi.org/10.20862/0042-4676-2021-102-5-284-295.
Full textKim, Ka Eun, Dong Hyun Sinn, Moon Seok Choi, and Honsoul Kim. "Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment." PLOS ONE 17, no. 1 (January 27, 2022): e0262750. http://dx.doi.org/10.1371/journal.pone.0262750.
Full textBesa, Cecilia, Suguru Kakite, Nancy Cooper, Marcelo Facciuto, and Bachir Taouli. "Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T." Acta Radiologica Open 4, no. 2 (February 1, 2015): 204798161456128. http://dx.doi.org/10.1177/2047981614561285.
Full textLomovtseva, Karina K., and G. G. Karmazanovsky. "The possibility of applying magnetic resonance imaging with hepatospecific contrast agent." Clinical Medicine (Russian Journal) 96, no. 3 (July 20, 2018): 213–21. http://dx.doi.org/10.18821/0023-2149-2018-96-3-213-221.
Full textRibeiro, Bruno Jucá, Aldo Maurici Araújo Alves, Rafael Santiago de Oliveira, Fernanda Velloni, and Giuseppe D’Ippolito. "The role of gadoxetic acid-enhanced magnetic resonance cholangiography in the evaluation of postoperative bile duct injury: pictorial essay." Radiologia Brasileira 52, no. 6 (December 2019): 403–7. http://dx.doi.org/10.1590/0100-3984.2018.0089.
Full textRenzulli, Matteo, Alfredo Clemente, Anna Maria Ierardi, Irene Pettinari, Francesco Tovoli, Stefano Brocchi, Giuliano Peta, Salvatore Cappabianca, Gianpaolo Carrafiello, and Rita Golfieri. "Imaging of Colorectal Liver Metastases: New Developments and Pending Issues." Cancers 12, no. 1 (January 8, 2020): 151. http://dx.doi.org/10.3390/cancers12010151.
Full textDissertations / Theses on the topic "Acido Gadoxetico"
Lu, Yi Cheng. "Classifying Liver Fibrosis Stage Using Gadoxetic Acid-Enhanced MR Images." Thesis, Linköpings universitet, Institutionen för medicin och hälsa, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-162989.
Full textPRADELLA, SILVIA. "Effects of age and Gadoxetic Acid on quantitative DW Imaging of the liver." Doctoral thesis, 2013. http://hdl.handle.net/2158/800876.
Full textElbakkoush, Abdallah Ahmed, and 艾伯樺. "Hepatobiliary transit times of Gadoxetic Acid in Magnetic Resonance Imaging of patients with liver cirrhosis." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/75963994034199480462.
Full text國立陽明大學
生物醫學影像暨放射科學系
102
Background and Objective: Chronic liver disease and cirrhosis result in about 35,000 deaths each year in the United States. Cirrhosis is the ninth leading cause of death in the United States and is responsible for 1.2% of all US deaths. MRI has been reported to be an excellent imaging modality because of its high tissue contrast and use of tissue-specific contrast agents. Gadoxetic acid (Gd-EOB-DTPA) is a more recently developed liver specific MR imaging contrast agent. The excretion of Gd-EOB-DTPA might be related to the liver disease and liver function. The pur¬pose of this study was to determine transit times for excretion of Gd-EOB-DTPA in the hepatobiliary system in patients with liver cirrhosis1. Material and Methods: Institutional Review Board of our hospital approved the study; in-formed consent was waived. We retrospectively included consecutive patients with liver cirrho¬sis who underwent contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2012. Finally, the 47 patients were en-rolled in this study. The Gd-EOB-DTPA-enhanced MRI included arterial phase (18~20sec, arterial phase, AP), por¬tal venous phase (50~55 sec, portal venous phase, PP), venous phase (85~90s, venous phase, VP) and three delayed phases (180s, 20mins and 30mins after the injection of contrast agent). The images were evaluated for the presence of contrast agent in the intra-hepatic bile ducts (IHD), the common bile duct (CBD), the gallbladder and the duodenum in AP, PP, VP and three delay phases. Results: The optimal time of arterial phase was from 15 s after injection, and the optimal time for portal venous imaging was from 40 s after injection. Meanwhile, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (39/47, 83 %) at the IHD and 37 patients (37/47, 78.5%) at the CBD. Gallbladder reflux was visible in 26 (26/47, 43%), duodenal excretion in 17 patients (17/47, 36%), respectively. After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (6/47, 13 %) at the IHD and 7 patients (7/47, 15 %) at the CBD, and gallbladder reflux was visible in 10 (10/47, 21%), duodenal excretion in 20 patients (26/47, 55%), respectively.(Fig 2 and Fig 3) GB was not visible in 9 patients, 4 out of these 9 patients received cholecystectomy. Conclusion: The results of our study shows that in patients with liver cirrhosis, the excretion of Gd-EOB-DTPA can be observed. Our results also demonstrated that the bilirubin level and the severity of cirrhosis (according to the Child Pugh scores had certain effect on excretion of Gd-EOB-DTPA into biliary tree.
Conference papers on the topic "Acido Gadoxetico"
Mandorfer, M., N. Bastati, L. Beer, S. Pötter-Lang, D. Tamandl, B. Yesim, MC Elmer, et al. "Functional Liver Imaging Score derived from gadoxetic acid-enhanced MRI predicts outcomes in patients with chronic liver disease." In 52. Jahrestagung & 30. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1691858.
Full textWei, Jingwei, Dongsheng Gu, Di Dong, Shuaitong Zhang, Yushen Jin, and Jie Tian. "Abstract 1294: Preoperative prediction of microvascular invasion in HCC using radiomics on multisequence gadoxetic acid-enhanced MR images." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1294.
Full textMandorfer, M., L. Haider, Z. Güngören, T. Reiberger, N. Bastati, JC Hodge, D. Chromy, et al. "Gadoxetic acid enhanced MRI distinguishes advanced chronic liver disease patients with improving liver function after sustained virologic response and patients with persistent liver damage." In 51. Jahrestagung & 29. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1654647.
Full text